Is CRBU or CRSP more undervalued in 2026?

CirclFi compares Caribou Biosciences, Inc. (CRBU) and CRISPR Therapeutics AG (CRSP) using 13 institutional-grade valuation models. CRBU has a Quality of Company score of 5.4/10 while CRSP scores 6.2/10.

Which is a better buy — CRBU or CRSP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRBU and CRSP valuations compare?

CRBU at $2.31 and CRSP at $56.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRBU vs CRSP Valuation Comparison 2026 — Intrinsic Value Analysis

CRBU

Biotechnology

Caribou Biosciences, Inc.

Quality

5.4

out of 10

Value Trap

LOW

Price

$2.31

Last close

Models

9/13

Active

CRSP

Biotechnology

CRISPR Therapeutics AG

Quality

6.2

out of 10

Value Trap

SAFE

Price

$56.38

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CRBU Fair Value	CRBU Upside	CRSP Fair Value	CRSP Upside
Bayesian DCF	Intrinsic	$0.56	-75.6%	$10.94	-80.6%
Earnings Power Value	Intrinsic	—	—	$27.66	-43.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.52	-34.3%	$8.56	-84.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRBU vs CRSP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRBU vs CRSP — Which Stock Is More Undervalued?

CRSP scores higher with a 6.2/10 quality rating vs CRBU's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Caribou Biosciences, Inc. (CRBU) and CRISPR Therapeutics AG (CRSP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRBU currently trades at $2.31 with a QOC of 5.4/10, while CRSP trades at $56.38 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).